Peter Ghali
Overview
Explore the profile of Peter Ghali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaezi A, Ashby T, Schweitzer M, Ghali P, Mirsaeidi M
Clin Transl Gastroenterol
. 2024 Jun;
15(9):e1.
PMID: 38822801
Introduction: We aim to investigate the contribution of interstitial lung disease (ILD) to mortality in patients with inflammatory bowel disease (IBD). Methods: We performed a comprehensive retrospective, population-based epidemiological study...
2.
Ghali P, Ibrahim R, Hodge D, White L, Wadei H
Clin Transplant
. 2024 Apr;
38(4):e15311.
PMID: 38616569
Background: Simultaneous liver kidney (SLK) transplant protects against acute cellular rejection. In 2017, UNOS implemented a "safety net" policy to allow patients with renal recovery to avoid renal transplantation. Whether...
3.
Attieh R, Ibrahim R, Ghali P, Keaveny A, Croome K, Hodge D, et al.
Liver Transpl
. 2023 Nov;
30(6):582-594.
PMID: 38015446
The number of kidney after liver transplants (KALT) increased after the implementation of the United Network of Organ Sharing (UNOS) safety net policy, but the effects of the policy on...
4.
Fialho A, Fialho A, Ribeiro B, Malespin M, De Melo S, Schey R, et al.
Cureus
. 2023 Jan;
15(1):e34042.
PMID: 36699110
Background A possible association between (HP) infection and liver diseases including steatosis is suspected. There is a lack of studies evaluating the association of HP and liver steatosis severity using...
5.
Tam E, Tremblay J, Fraser C, Conway B, Ramji A, Borgia S, et al.
Can Liver J
. 2022 Aug;
3(3):251-262.
PMID: 35992533
Background: Canada was the first country to approve elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic HCV infection for genotypes 1 and 4 with or without ribavirin and genotype 3 with...
6.
Benmassaoud A, Deschenes M, Chen T, Ghali P, Sebastiani G
Can Liver J
. 2022 Aug;
3(3):237-250.
PMID: 35992526
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. Non-alcoholic steatohepatitis (NASH), which is the progressive counterpart of the disease, is becoming...
7.
Sebastiani G, Patel K, Ratziu V, Feld J, Neuschwander-Tetri B, Pinzani M, et al.
Can Liver J
. 2022 Aug;
5(1):61-90.
PMID: 35990786
Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD...
8.
Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M, et al.
World J Hepatol
. 2022 Jan;
13(12):2179-2191.
PMID: 35070018
Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) seem common after liver transplantation. Aim: To investigate incidence and predictors of NAFLD and NASH by employing noninvasive testing in...
9.
Shengir M, Chen T, Guadagno E, Ramanakumar A, Ghali P, Deschenes M, et al.
JGH Open
. 2021 Apr;
5(4):434-445.
PMID: 33860093
Background And Aim: Non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) are prevalent conditions sharing common pathogenic factors. We performed a systematic literature review and meta-analysis aiming to...
10.
AlQallaf A, Alam A, Sapir-Pichhadze R, Ghali P, Cantarovich M
Exp Clin Transplant
. 2021 Mar;
19(3):231-236.
PMID: 33719946
Objectives: Kidney dysfunction is common in liver transplant candidates and is a well-established predictor of increased mortality after liver transplant. However, the best method for determination of the glomerular filtration...